A. d'Arminio-Monforte

发表

The changing face of HIV/AIDS in treated patients.

B. Clotet, E. Negredo, G. Sirera, 2009, Current HIV research.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Increased expression of IgG Fc receptor type I on neutrophils and monocytes from HIV‐infected subjects

C. Zanussi, G. Rizzardi, F. Capsoni, 1992, Clinical and experimental immunology.

Significant link between sCD30 changes and HIV viremia in patients treated with HAART

A. Lazzarin, N. Abrescia, P. Biswas, 2006, Journal of medical virology.

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice

A. Antinori, A. Gori, G. Lapadula, 2014, Journal of the International AIDS Society.

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

M. Moroni, G. Filice, R. Maserati, 2006, The Journal of antimicrobial chemotherapy.

The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression

A. Mocroft, O. Kirk, J. Gatell, 2012, Antiviral therapy.

Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences.

M. Moroni, G. Ippolito, A. Vandamme, 2001 .

Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation

G. Ippolito, C. Perno, C. Balotta, 2002, AIDS.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors

M. Moroni, C. Balotta, M. Galli, 2000, Antimicrobial Agents and Chemotherapy.

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

A. Antinori, A. De Luca, C. Mussini, 2011, BMC infectious diseases.

Increasing Prevalence of Non‐Clade B HIV‐1 Strains in Heterosexual Men and Women, as Monitored by Analysis of Reverse Transcriptase and Protease Sequences

M. Moroni, G. Ippolito, A. Vandamme, 2001, Journal of acquired immune deficiency syndromes.

Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process

D. Richman, R. Rajasuriar, G. Behrens, 2021, HIV Medicine.

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

D. Podzamczer, J. Gatell, P. Reiss, 2003, AIDS.

Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.

M. Moroni, M. D. De Pasquale, M. Galli, 1997, Antiviral therapy.

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

M. Zwahlen, A. Mocroft, O. Kirk, 2020, Clinical Infectious Diseases.

First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006)

M. Moroni, C. Giannattasio, A. Lazzarin, 2007, Infection.

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

J. Sterne, A. Sabin, A. Mocroft, 2018, HIV medicine.

Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.

M. Moroni, F. Adorni, M. Galli, 1999, Journal of acquired immune deficiency syndromes.

Pathological findings in the central nervous system of AIDS patients on assumed antiretroviral therapeutic regimens: retrospective study of 1597 autopsies

P. Duca, M. Nebuloni, L. Vago, 2002, AIDS.

Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.

M. Moroni, G. Ippolito, A. Lazzarin, 2002, Journal of biological regulators and homeostatic agents.

Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral-naive patients starting highly active antiretroviral therapy

L. Minoli, C. Perno, C. Balotta, 2002 .

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

B. Gazzard, A. Mocroft, O. Kirk, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.